Skip to content
StockMarketAgent
Sector pending / Biological Products, Except Diagnostic SubstancesUpdated 2026-05-10 22:07 UTC

FRA/GE91 stock hub

FRA/GE91 has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

FRA/GE91is not in this month’s coverageGet our monthly research letter — no spam
Fair value midpoint
n/a
Fair value pending
Upside to midpoint
n/a
Based on latest report
Confidence
n/a
Data quality and model convergence
Market cap
13.5B
Frankfurt Stock Exchange
Market data

Live price

Current market quote for this ticker.

Current price
FRA/GE91
In the news

Latest news · FRA/GE91

Recent company headlines from major financial publishers.

Loading
Fetching the latest headlines.
Loading
Fetching the latest headlines.
Loading
Fetching the latest headlines.
Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming
DateLoading
Window
EPS estimate
Revenue estimate
Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E19.2
P25 n/aP50 n/aP75 n/a
Trailing P/E18.9
P25 n/aP50 n/aP75 n/a
ROE15
P25 n/aP50 n/aP75 n/a
ROIC10.7
P25 n/aP50 n/aP75 n/a
Benchmarks - 1M
S&P 500n/a
Nasdaq Compositen/a
Dow Jones Industrial Averagen/a
Russell 2000n/a
Indicator catalog

All FRA/GE91 market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields
203
Groups with data
11
Currency
USD
Showing 203 of 203 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

18
MetricValue
Country
Denmark
Country code
DE
Employees
3,088
Employees Change
450%
Employees Change Percent
17.06
Enterprise value
EUR 16.8B
Exchange
Frankfurt Stock Exchange
Financial currency
USD
First seen
2026-05-10
Industry
Biological Products, Except Diagnostic Substances
Last refreshed
2026-05-10
Market cap
EUR 13.5B
Price
EUR 22.4
Price currency
EUR
Rev Per Employee
1,095,640.32x
Sic
2836
Symbol
fra/GE91
Website
https://www.genmab.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

14
MetricValue
Earnings Yield
5.28%
EV Earnings
23.6x
EV/EBIT
15.05x
EV/EBITDA
14.38x
EV/FCF
22.22x
EV/Sales
4.97x
FCF yield
5.61%
Forward P/E
19.16x
P/B ratio
2.74x
P/E ratio
18.94x
P/S ratio
3.99x
PE Ratio10 Y
43.38x
PE Ratio3 Y
21.58x
PE Ratio5 Y
32.49x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

24
MetricValue
EBIT Margin
32.99%
EBITDA Margin
34.09%
FCF margin
22.35%
Gross margin
93.31%
Gross Profit
EUR 3.2B
Gross Profit Growth
18.37%
Gross Profit Growth Q
23.48%
Gross Profit Growth3 Y
17.93%
Gross Profit Growth5 Y
16.39%
Net Income
EUR 712.1M
Net Income Growth
-27.73%
Net Income Growth Q
-72.82%
Net Income Growth3 Y
2.7%
Net Income Growth5 Y
-1.41%
Pretax Margin
26.51%
Profit Margin
21.05%
Profit Per Employee
EUR 230,587
ROA
8.48
Roa5y
10.27
ROCE
11.49
ROE
14.96
Roe5y
18.28
ROIC
10.72
Roic5y
66.47

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

19
MetricValue
Cagr1y
19.8%
Cagr3y
-14.94%
Cagr5y
-6.17%
EPS Growth
-25.81
EPS Growth Q
-72.79
EPS Growth3 Y
4.5
EPS Growth5 Y
-0.38
FCF Growth
-24.76%
FCF Growth3 Y
-1.18%
FCF Growth5 Y
0.36%
OCF Growth
-24.46%
OCF Growth Q
-98.96%
OCF Growth10 Y
32.34%
OCF Growth3 Y
-1.94%
OCF Growth5 Y
0.04%
Revenue Growth
20.66x
Revenue Growth Q
25.32x
Revenue Growth3 Y
20.68x
Revenue Growth5 Y
18.01x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

21
MetricValue
Asset Turnover
EUR 0.41
Assets
EUR 10.7B
Cash
EUR 1.3B
Current Assets
EUR 2.2B
Current Liabilities
EUR 998.9M
Debt
EUR 4.6B
Debt EBITDA
EUR 3.97
Debt Equity
EUR 0.94
Debt FCF
EUR 6.14
Equity
EUR 4.9B
Interest Coverage
7.66
Liabilities
EUR 5.8B
Long Term Assets
EUR 8.6B
Long Term Liabilities
EUR 4.8B
Net Cash
EUR -3.3B
Net Cash By Market Cap
EUR -24.6
Net Debt EBITDA
EUR 2.88
Net Debt Equity
EUR 0.67
Net Debt FCF
EUR 4.39
Tangible Book Value
EUR -3.1B
Tangible Book Value Per Share
EUR -51.16

Liquidity

Current-asset coverage and working-capital efficiency metrics.

6
MetricValue
Current ratio
2.18
Inventory Turnover
15.82
Net Working Capital
EUR 141.4M
Quick ratio
2.17
Working Capital
EUR 1.2B
Working Capital Turnover
EUR 1.45

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

1
MetricValue
Buyback Yield
2.55%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

33
MetricValue
1Y total return
19.79%
200-day SMA
24.54
3Y total return
-38.46%
50-day SMA
23.26
50-day SMA vs 200-day SMA
50under200
5Y total return
-27.27%
All Time High
44.4
All Time High Change
-49.55%
All Time High Date
2022-12-01
All Time Low
15.9
All Time Low Change
40.88%
All Time Low Date
2025-04-11
ATR
0.49
Ch YTD
-18.25
High
22.4
High52
29.8
High52 Date
2026-01-15
High52ch
-24.83%
Low
22.4
Low52
17
Low52 Date
2025-05-15
Low52ch
31.77%
Ma50ch
-3.71%
Price vs 200-day SMA
-8.72%
RSI
43.62
RSI Monthly
45.81
RSI Weekly
40.99
Sharpe ratio
0.82x
Sortino ratio
1.38
Total Return
2.55%
Tr YTD
-18.25
Tr1m
-5.88%
Tr3m
-13.85%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

6
MetricValue
Operating Income
EUR 1.1B
Operating Income Growth
18.4
Operating Income Growth Q
19.68
Operating Income Growth3 Y
12.44
Operating Income Growth5 Y
3.72
Operating margin
32.99

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

6
MetricValue
Float
60,664,302%
Net Borrowing
4,595,954,040
Shares Insiders
1.18%
Shares Institutions
60.59%
Shares Qo Q
1.17%
Shares Yo Y
-2.55%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

55
MetricValue
Adjusted FCF
EUR 624.5M
Average Volume
22.95x
Bv Per Share
80.28
CAPEX
EUR -26M
Ch1m
-5.88
Ch1y
19.79
Ch3m
-13.85
Ch3y
-38.46
Ch5y
-27.27
Ch6m
-9.68
Change
-5.88%
Change From Open
0
Close
23.8
Days Gap
-5.88
Depreciation Amortization
36,462,366
Earnings Date
2026-05-07
EBIT
EUR 1.1B
EBITDA
EUR 1.2B
EPS
EUR 11.37
F Score
4
FCF
EUR 756.3M
FCF EV Yield
4.5x
Financing CF
4,011,262,500
Fiscal Year End
December
Founded
1,998
Goodwill
301,026,510
Graham Number
14.75673
Graham Upside
-34.12
Income Tax
EUR 184.7M
Investing CF
-4,864,685,700
Is Primary Listing
0
Last Earnings Date
2026-05-07
Last Report Date
2026-03-31
Lynch Fair Value
EUR 5.91
Lynch Upside
-73.6
Ma150
25.57
Ma150ch
-12.39%
Ma20
23.32
Ma20ch
-3.95%
Net CF
-84,995,400
Next Earnings Date
2026-08-06
Open
22.4
P FCF Ratio
17.83
P OCF Ratio
17.24
Ppne
224,709,930
Price Date
2026-05-08
Price EBITDA
EUR 11.69
Relative Volume
14.39x
Revenue
3,383,337,300x
SBC By Revenue
3.9x
Share Based Comp
131,829,600
Tax By Revenue
5.46x
Tax Rate
20.6%
Tr6m
-9.68%
Z Score
2.72
Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate
n/a
Named kill scenarios are reviewed before any bullish rating can stand.
Moat score
n/a
Business quality stays separate from stock attractiveness.
Forward P/E
n/a
Valuation uses the full report model stack, not a single multiple.
Next action
Research pending
Final action steps are kept in the recommendation tab.
Income

Does FRA/GE91 pay a dividend?

Capital-return profile for this ticker.

Performance

FRA/GE91 stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

1Y total return
+19.8%
S&P 500 1Y: n/a
3Y total return
-38.5%
S&P 500 3Y: n/a
5Y total return
-27.3%
S&P 500 5Y: n/a
10Y total return
n/a
S&P 500 10Y: n/a
Ownership

Who owns FRA/GE91?

Insider, institutional, and short-interest positioning.

Institutional ownership
+60.6%
Share of float held by funds and institutions
Insider ownership
+1.2%
Stake held by company insiders. Higher generally signals alignment.
Short interest
n/a
Float sold short by bearish positioning
Y/Y dilution
-2.6%
Negative means the company is buying back shares.
Technical

FRA/GE91 momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)
43.6
Neutral momentum band
Price vs 200-day MA
-8.7%
50/200-day relationship not available
Beta (5Y)
n/a
Sensitivity to the broader market
Sharpe ratio
0.82
Risk-adjusted return — higher is better; >1.0 is solid.
Questions

About FRA/GE91

Hub-level FAQ points readers to the deeper analysis pages.

What is the current fra/GE91 stock rating?

fra/GE91 is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full fra/GE91 analysis?

The full report lives at /stocks/fra/GE91/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for fra/GE91?

The latest report frames fra/GE91 around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the fra/GE91 page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.